Alemtuzumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Alemtuzumab and local guidelines before prescribing.
Mechanism
CD52 monoclonal antibody depleting lymphocytes.
Uses
Relapsing multiple sclerosis, CLL, transplant conditioning.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Infusion reactions, autoimmune thyroid disease, ITP, anti-GBM disease, infections.
Interactions
Live vaccines contraindicated.
Contraindications and cautions
Active infection, HIV, malignancy
Monitoring
Monthly FBC, creatinine, urinalysis; TFT
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Monthly blood and urine tests for 4 years after last dose; herpes prophylaxis.
More from the textbook: uses, cautions and other points
- Alemtuzumab (used in multiple sclerosis): Graves' disease in up to a third of patients.
Endocrinology: Thyroid disease - Alemtuzumab | Infusion (anti-CD52) | Secondary autoimmune disease (thyroid, ITP, kidney) - monthly blood and urine monitoring for years; stroke and infusion reactions
Neurology: Anatomy, Physiology and Pharmacology - Avoid teriflunomide (washout needed), fingolimod and other S1P modulators (stop 2 months before, with rebound risk), cladribine, alemtuzumab (wait 4 months) and mitoxantrone.
Neurology: Multiple Sclerosis and inflammatory disease - Alemtuzumab | Thyroid disease, ITP, anti-GBM; monthly monitoring for 4 years.
Neurology: Multiple Sclerosis and inflammatory disease - Alemtuzumab , interferon alpha | Autoimmune thyroid disease (Graves')
Endocrine: Anatomy Physiology and Pharmacology - Who gets it: Women aged 20–50 most often. Risk factors include a family history, smoking (especially for eye disease), other autoimmune disease, the postpartum period, and alemtuzumab treatment.
Endocrinology: Thyroid disease - Natalizumab / ocrelizumab / alemtuzumab | MS DMTs; PML (JC virus) / infections, hepatitis B / secondary autoimmunity.
Neurology: Anatomy, Physiology and Pharmacology - Alemtuzumab (IV, two courses) - very effective but high risk of secondary autoimmune disease; now restricted.
Neurology: Multiple Sclerosis and inflammatory disease
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (1 mention)
- Endocrinology: Thyroid disease (2 mentions)
- Neurology: Anatomy, Physiology and Pharmacology (2 mentions)
- Neurology: Multiple Sclerosis and inflammatory disease (6 mentions)
- Renal: Dialysis and Transplant (2 mentions)
- Haematology: Anatomy Physiology and Pharmacology (1 mention)
- Haematology: Haemoglobinopathies and Transfusion (1 mention)
- ID: Hospital infection, the immunocompromised host, vaccination and public health (1 mention)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (2 mentions)
- Clinical Immunology: Autoimmunity, autoantibodies and complement (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (6 mentions)